Immunogenic composition

Patent metadata

Field	Value
Publication number	US-11286283-B2
Application number	US-201816954306-A
Country	US
Kind code	B2
Filing date	Dec 19, 2018
Priority date	Dec 21, 2017
Publication date	Mar 29, 2022
Grant date	Mar 29, 2022

Abstract

The present invention discloses modified Staphylococcus aureus HIa proteins which show reduced tendency to aggregate, improving protein stability and yield. Said modified HIa proteins optionally also contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified HIa protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked to an amino acid residue of the modified HIa protein.

First claim

The invention claimed is:

1. An HIa protein comprising a first amino acid sequence being at least 80% identical to SEQ ID NO: 1, the HIa protein comprising: a) a substitution of histidine at position 48 of SEQ ID NO: 1 with cysteine, b) a substitution of glycine at position 122 of SEQ ID NO: 1 with cysteine, and c) optionally a substitution of histidine at position 35 of SEQ ID NO: 1.

2. The HIa protein of claim 1 , the histidine at position 35 of SEQ ID NO: 1 being substituted.

3. The HIa protein of claim 1 comprising: A) D/E-X-N-Z-S/T (SEQ ID NO: 11), wherein X and Z are independently any amino acid apart from proline, or B) K-D/E-X-N-Z-S/T-K (SEQ ID NO: 12), wherein X and Z are independently any amino acid apart from proline.

4. The HIa protein of claim 1 , the first amino acid sequence being at least 85% identical to the amino acid sequence of SEQ ID NO: 3.

5. The HIa protein of claim 1 further comprising a peptide tag optionally comprising a hex-histidine tag or a histidine-arginine repeat and optionally being at the C-terminus of the HIa protein.

6. The HIa protein of claim 5 , the first amino acid sequence being at least 97% identical to any one of SEQ ID NOs: 5, 6, 9, or 10.

7. The HIa protein of claim 1 further comprising a signal sequence, which is capable of directing the HIa protein to the periplasm of a host cell, optionally the signal sequence being selected from any one of SEQ ID NOs: 13-21, and optionally the signal sequence being at the N-terminus of the HIa protein.

8. The HIa protein of claim 7 further comprising one or two amino acids between the signal sequence and the first amino acid sequence wherein optionally the HIa protein comprises a second amino acid sequence being at least 97% identical to SEQ ID NO: 5 or SEQ ID NO: 9.

9. The HIa protein of claim 1 further comprising one or two amino acids at the N-terminus of the HIa protein.

10. The HIa protein of claim 9 comprising a third amino acid sequence being at least 97% to SEQ ID NO: 6 or SEQ ID NO: 10.

11. A conjugate comprising an antigen and the HIa protein of claim 1 , wherein the HIa protein is linked to the antigen.

12. A polynucleotide encoding the HIa protein of claim 1 .

13. A vector comprising the polynucleotide of claim 12 .

14. A host cell comprising:
i) one or more nucleic acids that encode glycosyltransferase(s);
ii) a nucleic acid that encodes an oligosaccharyl transferase;
iii) a nucleic acid that encodes the HIa protein according to claim 1 ;
and optionally
iv) a nucleic acid that encodes a polymerase.

15. A method comprising (i) culturing the host cell of claim 14 under conditions suitable for the production of proteins, thereby producing a composition comprising the host cell and a bioconjugate comprising a saccharide and the HIa protein, the HIa protein being linked to the saccharide, and (ii) isolating the bioconjugate from the host cell.

16. A bioconjugate produced by the method of claim 15 , wherein said bioconjugate comprises a saccharide linked to a HIa protein.

17. An immunogenic composition comprising an immunologically effective amount of the HIa protein of claim 1 .

18. The immunogenic composition of claim 17 further comprising a pharmaceutically acceptable excipient or carrier.

19. A method for the treatment of Staphylococcus aureus infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the HIa protein of claim 1 .

20. A method of inducing an immune response to Staphylococcus aureus in a subject, the method comprising administering to the subject an effective amount to induce the immune response of the HIa protein of claim 1 .

Assignees

• Glaxosmithkline Biologicals Sa

Inventors

• Braun Martin
• Faridmoayer Amirreza
• Gerber Sabina Marietta
• Mueller Markus

Classifications

• A61K47/6415

  Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins · CPC title

• C07K14/31 Primary

  from Staphylococcus (G) · CPC title

• C07K2319/034

  containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K39/085 Primary

  Staphylococcus · CPC title